陕产具柄重楼的生药学研究
|
摘要
目的:研究陕产具柄重楼根茎的生药学特征。方法:采用形态组织学鉴别方法,研究原植物形态、生药性状和显微特征,用HPLC法测定重楼皂苷Ⅰ、Ⅱ、Ⅵ、Ⅶ的总含量。结果:陕产具柄重楼原植物来源清楚。根茎显微特征:横切面有栓化表皮、皮层和显著内皮层、薄壁组织中散布周木式维管束的中柱等结构;生药粉末中含极多单粒淀粉,常见草酸钙针晶,环纹和网纹导管,较少栓化表皮细胞。HPLC法测定4种重楼皂苷的总含量达0.9%以上。结论:陕产具柄重楼来源确定、生药性状稳定,具有特定显微结构,重楼皂苷Ⅰ、Ⅱ、Ⅵ、Ⅶ总含量均达到2015版《中国药典》标准。该研究阐释了民间将具柄重楼根茎与《药典》所载中药重楼同名等效使用的合理性,为制订具柄重楼质量标准,寻求中药重楼替代资源、有效指导重楼中药材种植奠定了基础。
Objective: To research the characteristics of pharmacognosy of rhizome crude medicine of Paris fargesii Franch. var. petiolata(Baker ex C.H.Wright) Wang et Tang from Shaanxi province. Methods: The morphology, pharmacognosy and microscopical characteristics of Paris fargesii Franch. var. petiolata(Baker ex C.H.Wright) Wang et Tang from Shaanxi province are studied by morphology and histology identification. And HPLC was adopted in the content determination of the total content of 4 saponins(polyphyllins Ⅰ,Ⅱ,Ⅵ and Ⅶ). Results: The plant origin of Paris fargesii Franch. var. petiolata(Baker ex C.H.Wright) Wang et Tang from Shaanxi province was explicit. The microscopic characteristics of the rhizome as follows: In the transection section,suberificationepidermis, cortex and remarkable endodermis, and some stele of amphivasal vascular bundle in the parenchyma tissue were observed. And a great manysimple starch grains were observed in the powder, common caiciumoxialate acicular crystal, annular vessel and reiculate vessel, and small amount of suberziration epidermis cells were observed in the medical material power. In addition, the total content of 4 saponins(polyphyllinsⅠ,Ⅱ,Ⅵ andⅦ) reached 0.9%. Conclusion: Paris fargesii Franch. var. petiolata(Baker ex C.H.Wright) Wang et Tang from Shaanxi province have definiteorigin sources, stable pharmacognosical characteristics and specific microstructures, and content of 4 saponins(polyphyllins Ⅰ, Ⅱ, Ⅵ and Ⅶ) metthe requirement of Chinese Pharmacopoeia(2015). The results explain that the Paris fargesii Franch. var. petiolata(Baker ex C.H.Wright) Wang et Tang use as PARIDIS RHIZOMAE recorded in the Chinese Pharmacopoeia(2015) is reasonable, and may lay a foundation for formulating the quality standard of Paris fargesii Franch. var. petiolata(Baker ex C.H.Wright) Wang et Tang, developing alternative resources of PARIDIS RHIZOMAE, and directing the planting of Paris sp.
Objective: To research the characteristics of pharmacognosy of rhizome crude medicine of Paris fargesii Franch. var. petiolata(Baker ex C.H.Wright) Wang et Tang from Shaanxi province. Methods: The morphology, pharmacognosy and microscopical characteristics of Paris fargesii Franch. var. petiolata(Baker ex C.H.Wright) Wang et Tang from Shaanxi province are studied by morphology and histology identification. And HPLC was adopted in the content determination of the total content of 4 saponins(polyphyllins Ⅰ,Ⅱ,Ⅵ and Ⅶ). Results: The plant origin of Paris fargesii Franch. var. petiolata(Baker ex C.H.Wright) Wang et Tang from Shaanxi province was explicit. The microscopic characteristics of the rhizome as follows: In the transection section,suberificationepidermis, cortex and remarkable endodermis, and some stele of amphivasal vascular bundle in the parenchyma tissue were observed. And a great manysimple starch grains were observed in the powder, common caiciumoxialate acicular crystal, annular vessel and reiculate vessel, and small amount of suberziration epidermis cells were observed in the medical material power. In addition, the total content of 4 saponins(polyphyllinsⅠ,Ⅱ,Ⅵ andⅦ) reached 0.9%. Conclusion: Paris fargesii Franch. var. petiolata(Baker ex C.H.Wright) Wang et Tang from Shaanxi province have definiteorigin sources, stable pharmacognosical characteristics and specific microstructures, and content of 4 saponins(polyphyllins Ⅰ, Ⅱ, Ⅵ and Ⅶ) metthe requirement of Chinese Pharmacopoeia(2015). The results explain that the Paris fargesii Franch. var. petiolata(Baker ex C.H.Wright) Wang et Tang use as PARIDIS RHIZOMAE recorded in the Chinese Pharmacopoeia(2015) is reasonable, and may lay a foundation for formulating the quality standard of Paris fargesii Franch. var. petiolata(Baker ex C.H.Wright) Wang et Tang, developing alternative resources of PARIDIS RHIZOMAE, and directing the planting of Paris sp.
引文
[1]中国科学院中国植物志编辑委员会.中国植物志[M].15卷.北京:科学出版社,1978:88-96.
[2]中国科学院西北植物研究所.秦岭植物志(第一卷·第一册)[M].北京:科学出版社,1976:353-354.
[3]张志英.陕西中药名录[M].西安:陕西省科学技术出版社,1989:202.
[4]李世全.秦岭巴山天然药物志[M].西安:陕西科学技术出版社,1987:245-246.
[5]程虎印,王薇,程江雪.“七药”的资源特征及其研发策略[J].中草药,2014,45(15):2272-2276.
[6]程虎印,徐进,颜永刚,等.陕产重楼属药用植物的研究进展[J].陕西中医药大学学报,2017,40(1):107-110.
[7]陈彦生.陕西维管植物名录[M].北京:高等教育出版社,2016:429.
[8]程虎印,颜永刚,刘亮亮,等.陕产重楼属南重楼组药用植物分布新记录调查研究[J].中国中医药信息杂志,2018,25(3):1-6.
[9]杨远贵,张霁,张金渝,等.重楼属植物化学成分及药理活性研究进展[J].中草药,2016,47(18):3301-3323.
[10]刘湘丹,王朝辉,徐玉琴,等.中药材重楼研究进展[J].中医药导报,2015,20(15):90-93.
[11]张亚茹,彭献娜,王彩虹,等.重楼活性化学成分与药理作用研究进展[J].亚太传统医药,2015,11(2):39-40.
[12]赵飞亚,陶爱恩,夏从龙.基于国内专利结合资源、应用与开发现状的重楼发展策略探讨[J].中国中药杂志,2018,43(2):404-409.
[13]宋小妹,刘海静.太白七药研究与应用[M].北京:人民卫生出版社,2011:132-137.
[14] YU M J,XING H Y,ZHANG S S,et al. Contrastive Study on Content and Anti-oxidation Activity of Total Saponins from Cultivated and Willd Paris Plants in Southwest China[J].Medicinal Plant,2017,8(1):7-11.
[15]国家药典委员会.中国药典[M].北京:中国医药科技出版社,2015:260.
[16]肖培根.新编中药志[M].北京:化学工业出版社,2002:704-713.
[17]中国药材总公司.中国中药区划[M].北京:科学出版社,1995:312-316.
[18]杨光义,胡培,叶方,等.重楼资源分布与可持续利用研究进展[J].中国药师,2016,19(1):159-162.
[19]程虎印,刘亮亮,程江雪,等.华阴市产重楼属药用植物生态特点及资源状况调查[J].中国现代应用药学,2017,34(5):674-680.
[20]成莉,甄艳,陈敏,等.扩大重楼药用资源研究进展[J].中国中药杂志,2015,40(16):3121-3124.
[21]蒋露,康利平,刘大会,等.历代本草重楼基原考[J].中国中药杂志,2017,42(18):3469-3473.
[22]李恒,陈昌祥,丁靖凯.重楼属植物的化学成分、地理分布及资源评价[J].云南植物研究,1988(s1):38-46.
[23]王跃虎,牛红梅,张兆云,等.重楼属植物的药用价值及其化学物质基础[J].中国中药杂志,2015,40(5):833-839.
[24]杨德全,杨勤,周浓.多基源重楼的质量等同性研究[J].中国实验方剂学杂志,2014,20(3):91-94.
[25] WEI J C, GAO W Y, YAN X D, et al. Chemicalconsitituents of plants from the genus Paris[J].Chen Biodivers,2014,11(9):1277.
[26] ZHAO Y, KANG L P, LIU Y X, et al. Steroidalsuponins from the rhizome of Paris polyohylla and their cytotoxic activities[J].Plants Med,2009,75(4):356.
[27] LIU Z,ZHENG Q,CHEN W,et al. Chemosensitizing effect of Paris saponinⅠon camptothein and 10-hydroxycamptothein in lung cancer cells via p-38 MARK,ERK,and Akt signaling pathways[J].Eur J Med Chem,2016(125):760.
[28]卢伟,牟雄军,杨广义,等.中药重楼药理活性研究进展[J].中国药师,2017,20(5):896-899.
[29]赵庭周,王卜琼,马青,等.滇重楼采收期研究[J].中国野生植物资源,2014,33(5):61-66.
[30]刘立敏,赵志莲,韩多,等.不同生长年限滇重楼干物质积累量及活性成分积累的规律考察[J].中国医药工业杂志,2016,47(6):706-710.
[31]李艳敏,丁立帅,王晶晶,等.基于茎痕判定的不同生长年限重楼药材中皂苷含量分析[J].中国实验方剂学杂志,2016,22(12):42-46.
[32]童凯,孙旭,姜美杰,等.华重楼的形态多样性及其单株产量和质量的关系[J].中国中药杂志,2017,42(7):1300-1303.
[33]王强,徐国钧,李恒,等.中药重楼的显微鉴定研究Ⅰ[J].中国药科大学学报,1989,20(6):330-334.
[34]车志远,王启帆,李和伟.精准医学视角下关于中药用药的理性思考[J].中医药导报,2017,23(21):4-6.
[35]李冬雪.中药现代化建设成果及思考[J].中医药导报,2015,21(3):1-4.
[2]中国科学院西北植物研究所.秦岭植物志(第一卷·第一册)[M].北京:科学出版社,1976:353-354.
[3]张志英.陕西中药名录[M].西安:陕西省科学技术出版社,1989:202.
[4]李世全.秦岭巴山天然药物志[M].西安:陕西科学技术出版社,1987:245-246.
[5]程虎印,王薇,程江雪.“七药”的资源特征及其研发策略[J].中草药,2014,45(15):2272-2276.
[6]程虎印,徐进,颜永刚,等.陕产重楼属药用植物的研究进展[J].陕西中医药大学学报,2017,40(1):107-110.
[7]陈彦生.陕西维管植物名录[M].北京:高等教育出版社,2016:429.
[8]程虎印,颜永刚,刘亮亮,等.陕产重楼属南重楼组药用植物分布新记录调查研究[J].中国中医药信息杂志,2018,25(3):1-6.
[9]杨远贵,张霁,张金渝,等.重楼属植物化学成分及药理活性研究进展[J].中草药,2016,47(18):3301-3323.
[10]刘湘丹,王朝辉,徐玉琴,等.中药材重楼研究进展[J].中医药导报,2015,20(15):90-93.
[11]张亚茹,彭献娜,王彩虹,等.重楼活性化学成分与药理作用研究进展[J].亚太传统医药,2015,11(2):39-40.
[12]赵飞亚,陶爱恩,夏从龙.基于国内专利结合资源、应用与开发现状的重楼发展策略探讨[J].中国中药杂志,2018,43(2):404-409.
[13]宋小妹,刘海静.太白七药研究与应用[M].北京:人民卫生出版社,2011:132-137.
[14] YU M J,XING H Y,ZHANG S S,et al. Contrastive Study on Content and Anti-oxidation Activity of Total Saponins from Cultivated and Willd Paris Plants in Southwest China[J].Medicinal Plant,2017,8(1):7-11.
[15]国家药典委员会.中国药典[M].北京:中国医药科技出版社,2015:260.
[16]肖培根.新编中药志[M].北京:化学工业出版社,2002:704-713.
[17]中国药材总公司.中国中药区划[M].北京:科学出版社,1995:312-316.
[18]杨光义,胡培,叶方,等.重楼资源分布与可持续利用研究进展[J].中国药师,2016,19(1):159-162.
[19]程虎印,刘亮亮,程江雪,等.华阴市产重楼属药用植物生态特点及资源状况调查[J].中国现代应用药学,2017,34(5):674-680.
[20]成莉,甄艳,陈敏,等.扩大重楼药用资源研究进展[J].中国中药杂志,2015,40(16):3121-3124.
[21]蒋露,康利平,刘大会,等.历代本草重楼基原考[J].中国中药杂志,2017,42(18):3469-3473.
[22]李恒,陈昌祥,丁靖凯.重楼属植物的化学成分、地理分布及资源评价[J].云南植物研究,1988(s1):38-46.
[23]王跃虎,牛红梅,张兆云,等.重楼属植物的药用价值及其化学物质基础[J].中国中药杂志,2015,40(5):833-839.
[24]杨德全,杨勤,周浓.多基源重楼的质量等同性研究[J].中国实验方剂学杂志,2014,20(3):91-94.
[25] WEI J C, GAO W Y, YAN X D, et al. Chemicalconsitituents of plants from the genus Paris[J].Chen Biodivers,2014,11(9):1277.
[26] ZHAO Y, KANG L P, LIU Y X, et al. Steroidalsuponins from the rhizome of Paris polyohylla and their cytotoxic activities[J].Plants Med,2009,75(4):356.
[27] LIU Z,ZHENG Q,CHEN W,et al. Chemosensitizing effect of Paris saponinⅠon camptothein and 10-hydroxycamptothein in lung cancer cells via p-38 MARK,ERK,and Akt signaling pathways[J].Eur J Med Chem,2016(125):760.
[28]卢伟,牟雄军,杨广义,等.中药重楼药理活性研究进展[J].中国药师,2017,20(5):896-899.
[29]赵庭周,王卜琼,马青,等.滇重楼采收期研究[J].中国野生植物资源,2014,33(5):61-66.
[30]刘立敏,赵志莲,韩多,等.不同生长年限滇重楼干物质积累量及活性成分积累的规律考察[J].中国医药工业杂志,2016,47(6):706-710.
[31]李艳敏,丁立帅,王晶晶,等.基于茎痕判定的不同生长年限重楼药材中皂苷含量分析[J].中国实验方剂学杂志,2016,22(12):42-46.
[32]童凯,孙旭,姜美杰,等.华重楼的形态多样性及其单株产量和质量的关系[J].中国中药杂志,2017,42(7):1300-1303.
[33]王强,徐国钧,李恒,等.中药重楼的显微鉴定研究Ⅰ[J].中国药科大学学报,1989,20(6):330-334.
[34]车志远,王启帆,李和伟.精准医学视角下关于中药用药的理性思考[J].中医药导报,2017,23(21):4-6.
[35]李冬雪.中药现代化建设成果及思考[J].中医药导报,2015,21(3):1-4.